|
Feb 28
|
Q4 2023 Syndax Pharmaceuticals Inc Earnings Call
|
|
Feb 27
|
Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
|
|
Jan 15
|
IDEAYA Biosciences, Inc. (IDYA) Moves 7.6% Higher: Will This Strength Last?
|
|
Jan 8
|
Incyte Highlights Growth Opportunities and Provides Business Updates at the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Jan 6
|
EVP & Chief Medical Officer Steven Stein Sells Shares of Incyte Corp (INCY)
|
|
Dec 20
|
12 Most Promising Gene Editing Stocks According to Hedge Funds
|
|
Dec 19
|
13 Most Promising Healthcare Stocks According to Analysts
|
|
Dec 10
|
Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease
|
|
Dec 5
|
Incyte's Bullish Outlook: A Surprising Strength You Shouldn't Overlook
|
|
Dec 1
|
Sarepta Therapeutics (SRPT) Up 4.5% Since Last Earnings Report: Can It Continue?
|
|
Nov 30
|
Why Is Incyte (INCY) Down 1.8% Since Last Earnings Report?
|
|
Nov 5
|
Investors in Incyte (NASDAQ:INCY) from three years ago are still down 34%, even after 4.4% gain this past week
|
|
Nov 2
|
Incyte to Spotlight More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual Meeting
|
|
Sep 20
|
13 Best Beaten Down Stocks To Buy Now
|
|
Sep 18
|
Incyte Hits Five-Year Low After GSK Snags Approval For A New Jakafi Rival
|
|
Sep 18
|
Unveiling Incyte (INCY)'s Value: Is It Really Priced Right? A Comprehensive Guide
|
|
Sep 18
|
FDA approves GSK's unique myelofibrosis treatment Ojjaara
|
|
May 25
|
Data from Across Incyte’s Oncology Portfolio Accepted for Presentation at the 2023 ASCO Annual Meeting and EHA2023 Hybrid Congress
|